Search This Blog

Showing posts with label takeover. Show all posts
Showing posts with label takeover. Show all posts

Friday 20 August 2021

Ten days that shook the world: The latest Taliban takeover of Afghanistan

Najam Sethi in The Friday Times

The Afghan Taliban talked and fought. They won. The Americans talked and ran. They lost. The end was foretold in 2020 when President Donald Trump announced an exit from Afghanistan without installing a broad-based, inclusive interim government in Kabul. But few – certainly not President Biden who actually gave an unconditional cut-off date in September for full withdrawal but believed that the Afghan National Army could fight on for another year at least — expected the ANA to fold and President Ashraf Ghani to flee in ten days. This followed the last round of talks among the internal and external stakeholders in Doha, August 10-11.

​The Taliban’s brilliant strategy was based on the basic principles of guerilla warfare — gain Time to capture Space and use Space to erode the Will of the enemy to fight. This theory was first successfully enunciated by Mao Tse Tung in China in the 1930s and then by Ho Chi Minh in Vietnam in the 1960s. For a decade after their rout in 2001, the Taliban regrouped and reorganized on both sides of the Pakistan border, becoming bolder and more aggressive after 2010. But after signing the Agreement with the US in 2020, they dragged Time to forestall any US-selected “inclusive” government in Kabul while focusing on capturing Space in north Afghanistan – ethnically hostile regions led by warlords who had challenged and undermined their power in 1997-2001. Their tactics of talking and fighting on the front lines – “the Americans are leaving, lay down your weapons, surrender and go home, we won’t exact revenge or hurt you” – paid huge dividends. In the last stage, when the Americans began to progressively pull air support, commanders, trainers, contractors, and air supply lines to distant front lines were severely disrupted, the ANA lost critical elements of the war machine manufactured by the Americans, and crumbled. It didn’t help that massive corruption in the Ghani regime, including in the ANA, was a core demotivating factor, no less than the frequent shuffling of military commanders from the Presidency. The Taliban encirclement of Kabul was complete after the provincial garrison towns surrendered one after another and American soldiers caught their last flights home. 

​The biggest strategic mistake Ashraf Ghani made was fighting with Pakistan, a key stakeholder, and flirting with India, a distant spoiler. Pakistan’s stake in Afghanistan, for various reasons right or wrong, is forty years old. If Kabul couldn’t be overtly friendly with Islamabad, it should not have been overly hostile to it. Thus Pakistan and the Afghan Taliban became natural covert allies. The Americans, too, lost sight of the ball when they signed the 2020 Agreement by rejecting the Taliban’s demand to replace Ghani with an acceptable transitional option. What next?

​In America, President Biden – who was banking on popular goodwill for “bringing the boys home” by ending “America’s longest war” – is besieged with a popular backlash at another “Saigon moment”. Approval for his exit strategy has fallen radically among Democrats and Republicans from over 70% to under 50%. This implies that America might scapegoat Pakistan for its defeat. The anti-Pakistan narrative of “safe havens”, “Haqqani network is a veritable arm of the ISI”, “double-crossing”, etc, is already well established. If pushed, it could estrange Islamabad and derail international efforts to stabilize Afghanistan under an inclusive regime with regard for core human rights.

​In Afghanistan, the Taliban 2.0 can be expected to establish only a minimally acceptable inclusive regime with substantive levers of policy and power in their own hands. Initially they will try and run the country with an Amir ul Momineen or Supreme Leader at the helm of a handpicked Council of Ministers along the lines of Iran immediately after the Islamic Revolution. They will also crave international recognition and legitimacy by assuaging the fears of the regional powers – Russia, China, Iran, Central Asian States and Pakistan – by pledging economic cooperation and ending safe havens for regional militants, insurgents and separatists based in Afghanistan. For the international community, they will try to square their idea of human rights in an Islamic regime with Western notions of freedom and democracy.

​These factors are going to make or break the Taliban 2.0 regime. Al-Qaeda, TTP, ETM, IS, Daesh, Baloch separatists, etc., will not be easy to knock out or neutralize quickly. Their ranks have been swelled by the thousands of prisoners who have been released. If they continue to spill over across borders, tensions with neighbours will arise. If any Al-Qaeda attack on US soil is uncovered with footsteps going back to Afghanistan, America will come under pressure to exact revenge again.

​There is also the factor of Afghanistan 2.0. In the last two decades a new generation of Afghans has grown up in the light of secularism, media freedoms, women’s rights and information revolution. If the Taliban try to scuttle these in any brutal or swift manner, there will be a definite reaction at home and abroad with blowback consequences. Afghanistan 2.0’s economy — its financial system, education, administration and infrastructure , forex reserves, etc — are totally dependent on American largesse and aid.

Finally, much will depend on the experience and wisdom of the three top Taliban leaders who will guide Afghanistan into a new age. Their reputations and credentials precede them. The Supreme Leader, Haibatullah Akhunzada, was “an enthusiastic proponent of suicide bombings” who ordered his own son to blow himself up in an attack in Helmand province. He is also the strategist who fashioned the “talk talk, fight fight” strategy which proved so successful in the end. Sirajuddin Haqqani, number two, has been the “most dogged opponent” of the US who concentrated on “complex suicide attacks and targeted assassinations”. Abdul Ghani Baradar, who is the leading Presidential candidate, has served a decade in Pakistani prison on the say-so of the Americans.

​Pakistan is poised to win or lose big time. If Taliban 2.0 neutralize anti-Pakistan elements based in Afghanistan and facilitate the Pak-China CPEC corridor to Central Asia and the Central Asian rail, road, gas and oil corridor to South Asia, it will reap enormous dividends. But if the Taliban victory and American defeat raise the spectre of Islamic radicalism inside Pakistan either by emboldening disgruntled religious elements like the TLP or TTP or by triggering an anti-American populist wave that isolates Pakistan in the international community, the outlook will be bleak. Pakistan’s economy is totally dependent on the goodwill of the West and its civil society is sufficiently developed to resist any radical “Islamist” encroachments on their democratic freedoms.

​If the road to a Taliban victory in Afghanistan has been long and hard and bloody, the road ahead is neither secure nor assured. The predominantly Pashtun Taliban constitute only a small percentage of the 45-50% Pashtuns of Afghanistan. The other Pashtuns and ethnic regions may have surrendered to the Taliban military juggernaut but if they are not made real stakeholders in an inclusive broad based political and administrative state system, tribal revolts and foreign interventionists will start brewing once again in the bowels of Afghanistan.

Sunday 11 May 2014

Pfizer's bid for AstraZeneca shows that big pharma is as rotten as the banks


Global pharmaceutical companies are dodging the risks by loading R&D costs on to taxpayers
Pfizer plant
Every one of Pfizer’s patented drugs benefited from decades of taxpayer funds. Photograph: Canadian Press/Rex
Countries around the world are seeking long-run, innovation-led growth in the "real economy". This is born of a wish to move away from speculative growth led by short-term financial markets. For this reason, industrial policy is back on the agenda after years of being a near blasphemy.
The life-sciences industry is top of the list, for both Barack Obama and David Cameron, of "real" industries to nurture through such policy. But this month they have been reminded of an uncomfortable truth: big pharma is just as sick as the banks. And, like speculative finance, it is hurting taxpayers in the process.
Pfizer wants to buy AstroZeneca, a British firm, to cuts its high overheads and especially to pay the lower UK tax rate (20%) – the cheap way the UK attracts "capital"– rather than the 40% US tax rate. This is nothing new as Google and Apple have been shifting profits around the world to avoid tax. Even within the US, Apple moved one of its subsidiaries to Reno, Nevada to avoid paying higher tax in Cupertino, California. Let's call it a race to the bottom.
What makes this dynamic particularly problematic for the taxpayer is that the knowledge behind Apple and Pfizer products – the key to their long-run profits – has been virtually bankrolled by that same taxpayer. As I discuss in my book The Entrepreneurial State: Debunking Private vs Public Sector Myths, every technology behind the iPhone was publicly funded (internet, GPS, touch-screen, Siri) and every one of Pfizer's patented drugs benefited from decades of taxpayer funds through the US National Institutes of Health, which in 2012 alone spent £32bn (£19bn).
Indeed, Pfizer's recent shift of one of its largest R&D laboratories from Sandwich in Kent to Boston was not due to the lower taxes or regulation in Boston but to be closer to this pot of gold. Coming back to the UK only to suck more blood out of the system should warn the government of the kind of image it wants to present of itself. Is it happy to be played front and back?
And what is happening to big pharma's research and development? In the name of "open innovation" – the admission that most of their knowledge comes from small biotech and large public labs – big pharma have been closing down their own R&D (reducing total numbers of researchers), as well as moving the remaining ones to be close to those labs.
Big pharma is no longer in the innovation business, using its own resources to fund the high-risk ideas, most of which will fail. It has become more risk-averse and prefers to focus on the D of R&D and please shareholders. Mergers and acquisition strategies reduce expensive overheads and costs (of which research infrastructure is the highest).
Things become even clearer when we look at the numbers behind one of their biggest expenditures: share buybacks. These are geared to boost stock prices, stock options and executive pay. Indeed it is this type of dynamic that has been driving the extreme inequality described by Thomas Piketty. The calculations of Professor William Lazonick suggest that in 2011, along with $6.2bn paid in dividends, Pfizer repurchased $9bn in stock, equivalent to 90% of its net income and 99% of its R&D expenditures.
While the justification for such buybacks is often that there are no "opportunities for investment", the increased public funds in pharma research shows who is funding the opportunities and who is free-riding. Though in the end both lose since without an engaged private partner, innovation suffers.
To make matters worse, these "innovative" companies advising governments on their "life-sciences" strategies are constantly seeking handouts through R&D tax credits, or more recently through the UK  Patent Box tax scheme introduced in 2013 (as well as in the Netherlands, Belgium and Spain, and soon in the US), with a 10% tax for income earned on patented drugs.
Patents are already monopolies with 17 years' protection. There is no reason to increase profits even more during that time. Especially as what drives the research that leads to patents is not the "cost" of the research, but the opportunities that are perceived—historically driven by large amounts of risk-loving public funds.
Experts from the Institute for Fiscal Studies have argued that this policy will diminish government revenue by about £2bn a year, and have no effect on business investment in research – which was meant to be the point. Indeed, private investment tends to follow well-funded public investments, that are of course undermined by the constant bashing away at the ability of government to collect tax revenue. This not an innovation strategy but a City-like speculation strategy.
The parallel goes even further: just like the banks, big pharma socialises the risk, but privatises rewards. The few drugs that are coming out would not have emerged without taxpayer-funded research. Yet the taxpayer then pays twice: first for the research then for the high prices, justified by the supposedly high risk that big pharma is taking on. This is almost surreal: what risk? And what about taxpayer risk?
Rather than empty words on a life-sciences strategy, what is needed is for policymakers to become more confident in their negotiations with business. The 1980 Bayh-Dole act that allowed publicly funded research to be patented says that government should have a say on the prices of the drugs. The fact government has never exercised this right shows who has the upper hand.
But things can change. Innovation policy should be linked to corporate governance – why should companies that spend more on share buybacks than R&D benefit from public research funds? Then "intelligent" R&D tax credits could be created, linked not to the income generated from R&D but the research labour hired to conduct it (as introduced in the Netherlands).
Government could also retain a golden share of the intellectual property rights (patents) which public research produces, and/or make sure that the prices of the new drugs reflect how the taxpayer paid for the most high-risk research. And, finally, given the high dependence of the industry on publicly -funded R&D, do not allow acquisitions that undermine the underlying research base the companies themselves should commit to - and for which they constantly request handouts.
In short, we need to start fostering a more symbiotic innovation eco-system. It's time to put an end to the current, increasingly parasitic one. We could start by realising that government does have power to actively shape and create markets, and not just fix broken ones.